Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma

CenterWatch
14 Nov, 2019 ,

This study aims to determine if intermittent dosing is deliverable, based on patient and professional willing to take part in a randomized trial evaluating less rather than the standard duration of treatment. The trial will evaluate treatment compliance, Progression-Free Survival, and Quality of Life, to inform whether a subsequent definitive trial is justified and how it should be designed.

Source